Reducing meal-stimulated acid secretion versus reducing nocturnal acid secretion for healing of duodenal ulcer
- PMID: 2791799
- DOI: 10.1007/BF01537099
Reducing meal-stimulated acid secretion versus reducing nocturnal acid secretion for healing of duodenal ulcer
Abstract
Both meal-stimulated and nocturnal acid secretions have been shown to be abnormally increased in patients with duodenal ulcer. The relative efficacy of an acid-reducing regimen aimed specifically at controlling postprandial acid secretion compared with one that controls nocturnal acid secretion is, however, not known. The endoscopic healing rates at weeks 2, 4, 6, 8, 10, and 12 of three cimetidine regimens with identical total daily dose--bedtime (1200 mg), mealtime (400 mg three times a day with meals), and reference (200 mg three times a day with meals and 600 mg at bedtime)--were compared in a randomized study on 141 patients with endoscopically proven duodenal ulcer. Evaluating endoscopists were blinded to patients' form and duration of treatment and their clinical progress; patients were unaware of the comparative design of the study. Life-table analysis for the 12 weeks of observation revealed that the mealtime regimen resulted in significantly (P less than 0.05) better healing rates than either the bedtime or the reference regimen. The differences were accounted for largely by the significantly (P less than 0.04) better healing rate at two weeks with the mealtime regimen (68%) than with either the bedtime (47%) or the reference (45%) regimen. These findings indicate that a regimen that aims at controlling meal-stimulated acid secretion achieves a faster healing rate than one that aims at controlling nocturnal acid secretion in the treatment of duodenal ulcer, and they suggest that postprandial acid secretion plays a greater role than nocturnal acid secretion in the pathophysiology of this condition.
Similar articles
-
Duodenal ulcer healing by separate reduction of postprandial and nocturnal acid secretions have different pathophysiology.Gut. 1985 Oct;26(10):1038-44. doi: 10.1136/gut.26.10.1038. Gut. 1985. PMID: 4054701 Free PMC article. Clinical Trial.
-
Factors influencing healing of duodenal ulcer. Control of nocturnal secretion by H2 blockade and characteristics of patients who failed to heal.Dig Dis Sci. 1985 Jan;30(1):45-51. doi: 10.1007/BF01318370. Dig Dis Sci. 1985. PMID: 2856903 Clinical Trial.
-
Low-dose cimetidine in the acute treatment of duodenal ulcer. Comparison of a single nocturnal dose regimen with a twice daily regimen.J Gastroenterol Hepatol. 1990 Nov-Dec;5(6):669-74. doi: 10.1111/j.1440-1746.1990.tb01123.x. J Gastroenterol Hepatol. 1990. PMID: 2129838 Clinical Trial.
-
Antisecretory effect of three premeal doses of cimetidine 400 mg versus a single morning dose of omeprazole 20 mg: pathophysiological implications for duodenal ulcer treatment.Am J Gastroenterol. 1993 Jul;88(7):1088-92. Am J Gastroenterol. 1993. PMID: 8317411 Clinical Trial.
-
Comparative effects of two cimetidine regimens on 24-hour intragastric acidity in patients with asymptomatic duodenal ulcer.Clin Ther. 1984;6(3):259-81. Clin Ther. 1984. PMID: 6373006 Clinical Trial.
Cited by
-
Mealtime versus nighttime acid inhibition. A clinical pharmacological study with ranitidine.Dig Dis Sci. 1992 Sep;37(9):1368-72. doi: 10.1007/BF01296005. Dig Dis Sci. 1992. PMID: 1505287 Clinical Trial.
-
A comparative study of once-a-day morning and once-a-day bedtime administration of 40 mg famotidine in treating duodenal ulcers.Gastroenterol Jpn. 1992 Apr;27(2):179-86. doi: 10.1007/BF02777720. Gastroenterol Jpn. 1992. PMID: 1577222 Clinical Trial.
-
Variability in individual response to various doses of omeprazole. Implications for antiulcer therapy.Dig Dis Sci. 1994 Jan;39(1):161-8. doi: 10.1007/BF02090077. Dig Dis Sci. 1994. PMID: 8281852 Clinical Trial.